486 related articles for article (PubMed ID: 15227611)
1. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections.
Arbeit RD; Maki D; Tally FP; Campanaro E; Eisenstein BI;
Clin Infect Dis; 2004 Jun; 38(12):1673-81. PubMed ID: 15227611
[TBL] [Abstract][Full Text] [Related]
2. Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections.
Lipsky BA; Stoutenburgh U
J Antimicrob Chemother; 2005 Feb; 55(2):240-5. PubMed ID: 15659542
[TBL] [Abstract][Full Text] [Related]
3. [Daptomycin--a new antibiotic for the treatment of skin and soft tissue infections].
Mathiesen L; Midtvedt T; Solberg CO
Tidsskr Nor Laegeforen; 2006 Sep; 126(18):2383-4. PubMed ID: 16998552
[TBL] [Abstract][Full Text] [Related]
4. Daptomycin versus vancomycin for complicated skin and skin structure infections: clinical and economic outcomes.
Davis SL; McKinnon PS; Hall LM; Delgado G; Rose W; Wilson RF; Rybak MJ
Pharmacotherapy; 2007 Dec; 27(12):1611-8. PubMed ID: 18041881
[TBL] [Abstract][Full Text] [Related]
5. A pilot study of high-dose short duration daptomycin for the treatment of patients with complicated skin and skin structure infections caused by gram-positive bacteria.
Katz DE; Lindfield KC; Steenbergen JN; Benziger DP; Blackerby KJ; Knapp AG; Martone WJ
Int J Clin Pract; 2008 Sep; 62(9):1455-64. PubMed ID: 18662172
[TBL] [Abstract][Full Text] [Related]
6. The efficacy and safety of daptomycin: first in a new class of antibiotics for Gram-positive bacteria.
Rybak MJ
Clin Microbiol Infect; 2006 Mar; 12 Suppl 1():24-32. PubMed ID: 16445721
[TBL] [Abstract][Full Text] [Related]
7. Daptomycin: first in a new class of antibiotics for complicated skin and soft-tissue infections.
Kern WV
Int J Clin Pract; 2006 Mar; 60(3):370-8. PubMed ID: 16494659
[TBL] [Abstract][Full Text] [Related]
8. Safety and clinical outcomes when utilizing high-dose (> or =8 mg/kg) daptomycin therapy.
Moise PA; Hershberger E; Amodio-Groton MI; Lamp KC
Ann Pharmacother; 2009 Jul; 43(7):1211-9. PubMed ID: 19584384
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of daptomycin in complicated skin and skin-structure infections due to methicillin-sensitive and -resistant Staphylococcus aureus: results from the CORE Registry.
Martone WJ; Lamp KC
Curr Med Res Opin; 2006 Dec; 22(12):2337-43. PubMed ID: 17257448
[TBL] [Abstract][Full Text] [Related]
10. Postmarketing clinical experience in patients with skin and skin-structure infections treated with daptomycin.
Owens RC; Lamp KC; Friedrich LV; Russo R
Am J Med; 2007 Oct; 120(10 Suppl 1):S6-12. PubMed ID: 17904950
[TBL] [Abstract][Full Text] [Related]
11. Daptomycin versus other antimicrobial agents for the treatment of skin and soft tissue infections: a meta-analysis.
Bliziotis IA; Plessa E; Peppas G; Falagas ME
Ann Pharmacother; 2010 Jan; 44(1):97-106. PubMed ID: 19934396
[TBL] [Abstract][Full Text] [Related]
12. Daptomycin: rationale and role in the management of skin and soft tissue infections.
Seaton RA
J Antimicrob Chemother; 2008 Nov; 62 Suppl 3():iii15-23. PubMed ID: 18829721
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and duration of daptomycin therapy in resolving clinical symptoms in the treatment of complicated skin and skin structure infections.
Krige JE; Lindfield K; Friedrich L; Otradovec C; Martone WJ; Katz DE; Tally F
Curr Med Res Opin; 2007 Sep; 23(9):2147-56. PubMed ID: 17669231
[TBL] [Abstract][Full Text] [Related]
14. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms.
Stryjewski ME; Graham DR; Wilson SE; O'Riordan W; Young D; Lentnek A; Ross DP; Fowler VG; Hopkins A; Friedland HD; Barriere SL; Kitt MM; Corey GR;
Clin Infect Dis; 2008 Jun; 46(11):1683-93. PubMed ID: 18444791
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of daptomycin in the treatment of Gram-positive catheter-related bloodstream infections in cancer patients.
Chaftari AM; Hachem R; Mulanovich V; Chemaly RF; Adachi J; Jacobson K; Jiang Y; Raad I
Int J Antimicrob Agents; 2010 Aug; 36(2):182-6. PubMed ID: 20452752
[TBL] [Abstract][Full Text] [Related]
16. Management of cSSTIs: the role of daptomycin.
Garau J
Curr Med Res Opin; 2006 Nov; 22(11):2079-87. PubMed ID: 17076967
[TBL] [Abstract][Full Text] [Related]
17. Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens.
Carpenter CF; Chambers HF
Clin Infect Dis; 2004 Apr; 38(7):994-1000. PubMed ID: 15034832
[TBL] [Abstract][Full Text] [Related]
18. High-dose daptomycin for treatment of complicated gram-positive infections: a large, multicenter, retrospective study.
Kullar R; Davis SL; Levine DP; Zhao JJ; Crank CW; Segreti J; Sakoulas G; Cosgrove SE; Rybak MJ
Pharmacotherapy; 2011 Jun; 31(6):527-36. PubMed ID: 21923436
[TBL] [Abstract][Full Text] [Related]
19. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria.
Stryjewski ME; O'Riordan WD; Lau WK; Pien FD; Dunbar LM; Vallee M; Fowler VG; Chu VH; Spencer E; Barriere SL; Kitt MM; Cabell CH; Corey GR;
Clin Infect Dis; 2005 Jun; 40(11):1601-7. PubMed ID: 15889357
[TBL] [Abstract][Full Text] [Related]
20. Daptomycin for the treatment of surgical site infections.
Chamberlain RS; Culshaw DL; Donovan BJ; Lamp KC
Surgery; 2009 Aug; 146(2):316-24. PubMed ID: 19628091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]